GlassScriptPhysician profile
David M Wanalista
NPI 1497789077
$6,577.60
in general payments reported to CMS, 2019-2025
28 companies · $630 in 2025
The $630 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,334 · 2020: $1,700 · 2021: $1,223 · 2022: $712 · 2023: $580 · 2024: $399 · 2025: $630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,470 · Consulting Fee: $130 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,469.63 |
| Consulting Fee | $130.00 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,085.48 | 2019-2020 | |
| Ucb, INC. | $1,023.19 | 2019-2023 | Cimzia |
| Abbvie INC. | $848.69 | 2021-2025 | Rinvoq, Skyrizi |
| E.R. Squibb & Sons, L.L.C. | $539.59 | 2019-2021 | |
| Glaxosmithkline, LLC. | $420.57 | 2019-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $417.74 | 2019-2025 | |
| Lilly USA, LLC | $404.65 | 2019-2021 | |
| Janssen Biotech, INC. | $289.81 | 2019-2025 | Tremfya |
| Amgen INC. | $268.65 | 2019 | |
| Genzyme Corporation | $220.28 | 2019-2023 | |
| Cardinal Health 110 LLC | $200.00 | 2021-2022 | |
| Pfizer INC. | $152.87 | 2019-2023 | |
| Radius Health, INC. | $94.71 | 2023-2025 | Tymlos |
| Genentech USA, INC. | $92.68 | 2019 | |
| Mallinckrodt Hospital Products INC. | $83.45 | 2020-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $77.24 | 2022-2025 | Saphnelo |
| Organon LLC | $55.37 | 2022-2025 | Hadlima, Renflexis |
| Medexus Pharma, INC. | $42.39 | 2019 | |
| Aurinia Pharma U.S., INC. | $40.03 | 2021 | |
| Fidia Pharma USA INC. | $38.01 | 2023-2024 | Hymovis |
| Alvogen INC | $34.30 | 2021-2024 | Teriparatide |
| Pacira Therapeutics, INC. | $31.50 | 2019 | |
| Zimmer Biomet Holdings, INC. | $26.27 | 2019 | |
| Sandoz INC. | $21.43 | 2023 | Hyrimoz |
| Fresenius Kabi USA, LLC | $18.92 | 2024 | Idacio |
| Zyla Life Sciences, INC. | $17.29 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $16.99 | 2020 | |
| Merck Sharp & Dohme LLC | $15.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wanalista listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.